{"nctId":"NCT00793624","briefTitle":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I","startDateStruct":{"date":"2009-02"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":906,"armGroups":[{"label":"Olodaterol (BI 1744) Low","type":"EXPERIMENTAL","interventionNames":["Drug: Olodaterol (BI 1744)"]},{"label":"Olodaterol (BI 1744) High","type":"EXPERIMENTAL","interventionNames":["Drug: Olodaterol (BI 1744)"]},{"label":"Formoterol 12mcg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Formoterol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Olodaterol (BI 1744)","otherNames":[]},{"name":"Olodaterol (BI 1744)","otherNames":[]},{"name":"Formoterol","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:post-bronchodilator FEV1\\<80% of predicted normal (ECSC) and a post-bronchodilator FEV1/FVC \\<70% at Visit 1\n2. Male or female patients, 40 years of age or older\n3. Patients must be current or ex-smokers with a smoking history of more than 10 pack years:\n\nExclusion criteria:\n\n1. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT \\>x2 ULN, SGPT \\>x2 ULN, bilirubin \\>x2 ULN or creatinine \\>x2 ULN\n2. Patients with a history of asthma and/or total blood eosinophil count greater than 600/mm3\n3. Patients with thyrotoxicosis, paroxysmal tachycardia (\\>100 beats per minute)\n4. Patients with a history of myocardial infarction within 1 year of screening visit, unstable or life-threatening cardiac arrhythmia, hospitalization for heart failure within the past year, known active tuberculosis, a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years, life-threatening pulmonary obstruction, cystic fibrosis, clinically evident bronchiectasis, significant alcohol or drug abuse\n5. Patients who have undergone thoracotomy with pulmonary resection\n6. Patients being treated with oral beta-adrenergics or oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.\n7. Patients who regularly use daytime oxygen therapy for more than one hour per day.\n8. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program\n9. Pregnant or nursing women\n10. Women of childbearing potential not using two effective methods of birth control (one barrier and one non-barrier).","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.009","spread":"0.016"},{"groupId":"OG001","value":"0.142","spread":"0.015"},{"groupId":"OG002","value":"0.156","spread":"0.015"},{"groupId":"OG003","value":"0.168","spread":"0.015"}]}]}]},{"type":"PRIMARY","title":"Trough FEV1 Response at Week 24","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.056","spread":"0.015"},{"groupId":"OG001","value":"0.021","spread":"0.015"},{"groupId":"OG002","value":"0.028","spread":"0.015"},{"groupId":"OG003","value":"-0.002","spread":"0.015"}]}]}]},{"type":"PRIMARY","title":"Mahler Transitional Dyspnea Index Focal Score at 24 Weeks","description":"Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.046","spread":"0.255"},{"groupId":"OG001","value":"2.234","spread":"0.240"},{"groupId":"OG002","value":"2.068","spread":"0.245"},{"groupId":"OG003","value":"1.818","spread":"0.247"}]}]}]},{"type":"SECONDARY","title":"Saint George's Respiratory Questionnaire (SGRQ) Total Score at 24 Weeks","description":"Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.068","spread":"1.038"},{"groupId":"OG001","value":"38.627","spread":"0.995"},{"groupId":"OG002","value":"37.674","spread":"0.998"},{"groupId":"OG003","value":"40.116","spread":"0.994"}]}]}]},{"type":"SECONDARY","title":"Saint George's Respiratory Questionnaire (SGRQ) Total Score at 12 Weeks","description":"Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.105","spread":"1.027"},{"groupId":"OG001","value":"39.320","spread":"0.986"},{"groupId":"OG002","value":"36.961","spread":"0.989"},{"groupId":"OG003","value":"40.351","spread":"0.992"}]}]}]},{"type":"SECONDARY","title":"Saint George's Respiratory Questionnaire (SGRQ) Total Score at 48 Weeks","description":"Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.415","spread":"1.057"},{"groupId":"OG001","value":"38.545","spread":"1.000"},{"groupId":"OG002","value":"36.850","spread":"1.015"},{"groupId":"OG003","value":"40.431","spread":"1.015"}]}]}]},{"type":"SECONDARY","title":"Saint George's Respiratory Questionnaire (SGRQ) Total Score at 24 Weeks for Combined Analysis","description":"Saint George's Respiratory Questionnaire (SGRQ) measures the impact of COPD on overall health, daily life, and perceived well-being ranging from 0 (no limitations) to 100 (most limitations). This is a combined analysis of the data from NCT00793624 and NCT00796653 showing adjusted values using a MMRM model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.639","spread":"0.718"},{"groupId":"OG001","value":"38.794","spread":"0.693"},{"groupId":"OG002","value":"38.205","spread":"0.695"},{"groupId":"OG003","value":"40.391","spread":"0.699"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 2 Weeks","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.015","spread":"0.015"},{"groupId":"OG001","value":"0.201","spread":"0.015"},{"groupId":"OG002","value":"0.181","spread":"0.015"},{"groupId":"OG003","value":"0.221","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 6 Weeks","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.001","spread":"0.015"},{"groupId":"OG001","value":"0.178","spread":"0.015"},{"groupId":"OG002","value":"0.161","spread":"0.015"},{"groupId":"OG003","value":"0.194","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 12 Weeks","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.003","spread":"0.015"},{"groupId":"OG001","value":"0.176","spread":"0.015"},{"groupId":"OG002","value":"0.167","spread":"0.015"},{"groupId":"OG003","value":"0.182","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 48 Weeks","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.023","spread":"0.016"},{"groupId":"OG001","value":"0.122","spread":"0.015"},{"groupId":"OG002","value":"0.123","spread":"0.015"},{"groupId":"OG003","value":"0.149","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response at Week 2","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.019","spread":"0.015"},{"groupId":"OG001","value":"0.068","spread":"0.014"},{"groupId":"OG002","value":"0.060","spread":"0.014"},{"groupId":"OG003","value":"0.061","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response at Week 6","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.037","spread":"0.015"},{"groupId":"OG001","value":"0.049","spread":"0.014"},{"groupId":"OG002","value":"0.041","spread":"0.014"},{"groupId":"OG003","value":"0.042","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response at Week 12","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.027","spread":"0.015"},{"groupId":"OG001","value":"0.056","spread":"0.014"},{"groupId":"OG002","value":"0.048","spread":"0.014"},{"groupId":"OG003","value":"0.033","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response at Week 18","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.019","spread":"0.015"},{"groupId":"OG001","value":"0.046","spread":"0.014"},{"groupId":"OG002","value":"0.026","spread":"0.015"},{"groupId":"OG003","value":"0.023","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response at Week 32","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.023","spread":"0.015"},{"groupId":"OG001","value":"0.023","spread":"0.015"},{"groupId":"OG002","value":"0.026","spread":"0.015"},{"groupId":"OG003","value":"0.021","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response at Week 40","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.020","spread":"0.016"},{"groupId":"OG001","value":"0.020","spread":"0.015"},{"groupId":"OG002","value":"0.017","spread":"0.015"},{"groupId":"OG003","value":"0.004","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response at Week 48","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.065","spread":"0.015"},{"groupId":"OG001","value":"0.003","spread":"0.015"},{"groupId":"OG002","value":"-0.009","spread":"0.015"},{"groupId":"OG003","value":"-0.006","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.100","spread":"0.016"},{"groupId":"OG001","value":"0.277","spread":"0.016"},{"groupId":"OG002","value":"0.250","spread":"0.016"},{"groupId":"OG003","value":"0.290","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.081","spread":"0.016"},{"groupId":"OG001","value":"0.248","spread":"0.016"},{"groupId":"OG002","value":"0.234","spread":"0.016"},{"groupId":"OG003","value":"0.264","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 12 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.082","spread":"0.016"},{"groupId":"OG001","value":"0.247","spread":"0.016"},{"groupId":"OG002","value":"0.241","spread":"0.016"},{"groupId":"OG003","value":"0.256","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.068","spread":"0.017"},{"groupId":"OG001","value":"0.216","spread":"0.016"},{"groupId":"OG002","value":"0.225","spread":"0.016"},{"groupId":"OG003","value":"0.236","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.053","spread":"0.017"},{"groupId":"OG001","value":"0.192","spread":"0.016"},{"groupId":"OG002","value":"0.193","spread":"0.016"},{"groupId":"OG003","value":"0.215","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 2 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.076","spread":"0.028"},{"groupId":"OG001","value":"0.299","spread":"0.027"},{"groupId":"OG002","value":"0.311","spread":"0.027"},{"groupId":"OG003","value":"0.383","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 6 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.016","spread":"0.028"},{"groupId":"OG001","value":"0.252","spread":"0.027"},{"groupId":"OG002","value":"0.265","spread":"0.027"},{"groupId":"OG003","value":"0.326","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 12 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.023","spread":"0.028"},{"groupId":"OG001","value":"0.233","spread":"0.027"},{"groupId":"OG002","value":"0.278","spread":"0.027"},{"groupId":"OG003","value":"0.300","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.037","spread":"0.029"},{"groupId":"OG001","value":"0.220","spread":"0.027"},{"groupId":"OG002","value":"0.252","spread":"0.028"},{"groupId":"OG003","value":"0.279","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 48 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.016","spread":"0.029"},{"groupId":"OG001","value":"0.196","spread":"0.028"},{"groupId":"OG002","value":"0.219","spread":"0.028"},{"groupId":"OG003","value":"0.260","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response at Week 2","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.042","spread":"0.028"},{"groupId":"OG001","value":"0.110","spread":"0.027"},{"groupId":"OG002","value":"0.119","spread":"0.028"},{"groupId":"OG003","value":"0.126","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response at Week 6","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.046","spread":"0.029"},{"groupId":"OG001","value":"0.065","spread":"0.027"},{"groupId":"OG002","value":"0.085","spread":"0.028"},{"groupId":"OG003","value":"0.090","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response at Week 12","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.018","spread":"0.029"},{"groupId":"OG001","value":"0.079","spread":"0.028"},{"groupId":"OG002","value":"0.087","spread":"0.028"},{"groupId":"OG003","value":"0.068","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response at Week 18","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.060","spread":"0.029"},{"groupId":"OG001","value":"0.066","spread":"0.028"},{"groupId":"OG002","value":"0.078","spread":"0.028"},{"groupId":"OG003","value":"0.063","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response at Week 24","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.018","spread":"0.029"},{"groupId":"OG001","value":"0.038","spread":"0.028"},{"groupId":"OG002","value":"0.064","spread":"0.028"},{"groupId":"OG003","value":"0.001","spread":"0.029"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response at Week 32","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.019","spread":"0.030"},{"groupId":"OG001","value":"0.080","spread":"0.028"},{"groupId":"OG002","value":"0.084","spread":"0.028"},{"groupId":"OG003","value":"0.077","spread":"0.029"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response at Week 48","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.061","spread":"0.030"},{"groupId":"OG001","value":"0.022","spread":"0.028"},{"groupId":"OG002","value":"-0.002","spread":"0.029"},{"groupId":"OG003","value":"0.006","spread":"0.029"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response at Week 40","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.028","spread":"0.030"},{"groupId":"OG001","value":"0.087","spread":"0.028"},{"groupId":"OG002","value":"0.086","spread":"0.028"},{"groupId":"OG003","value":"0.052","spread":"0.029"}]}]}]},{"type":"SECONDARY","title":"Peak FVC (0-3h) Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.268","spread":"0.029"},{"groupId":"OG001","value":"0.454","spread":"0.028"},{"groupId":"OG002","value":"0.474","spread":"0.028"},{"groupId":"OG003","value":"0.551","spread":"0.029"}]}]}]},{"type":"SECONDARY","title":"Peak FVC (0-3h) Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.202","spread":"0.029"},{"groupId":"OG001","value":"0.411","spread":"0.028"},{"groupId":"OG002","value":"0.433","spread":"0.029"},{"groupId":"OG003","value":"0.467","spread":"0.029"}]}]}]},{"type":"SECONDARY","title":"Peak FVC (0-3h) Response After 12 Weeks","description":"Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.194","spread":"0.030"},{"groupId":"OG001","value":"0.382","spread":"0.029"},{"groupId":"OG002","value":"0.432","spread":"0.029"},{"groupId":"OG003","value":"0.450","spread":"0.029"}]}]}]},{"type":"SECONDARY","title":"Peak FVC (0-3h) Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.207","spread":"0.030"},{"groupId":"OG001","value":"0.379","spread":"0.029"},{"groupId":"OG002","value":"0.414","spread":"0.029"},{"groupId":"OG003","value":"0.424","spread":"0.029"}]}]}]},{"type":"SECONDARY","title":"Peak FVC (0-3h) Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline peak FVC was defined as the mean of the available pre-dose peak FVC values prior to first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.193","spread":"0.031"},{"groupId":"OG001","value":"0.344","spread":"0.029"},{"groupId":"OG002","value":"0.371","spread":"0.030"},{"groupId":"OG003","value":"0.416","spread":"0.030"}]}]}]},{"type":"SECONDARY","title":"Peak Expiratory Flow Rate (PEFR) at Week 24","description":"Weekly mean pre-dose morning and evening PEFR. Results are from non-MMRM ANCOVA models by week, with Last observation carried forward (LOCF) up to each week. Fixed effects include treatment, tiotropium, strata and baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"196.429","spread":"3.392"},{"groupId":"OG001","value":"211.496","spread":"3.420"},{"groupId":"OG002","value":"211.428","spread":"3.379"},{"groupId":"OG003","value":"214.070","spread":"3.373"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202.256","spread":"3.363"},{"groupId":"OG001","value":"219.977","spread":"3.408"},{"groupId":"OG002","value":"220.727","spread":"3.360"},{"groupId":"OG003","value":"220.129","spread":"3.332"}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Medication at Week 24","description":"Mean number of puffs of rescue medication used per day (daytime/nighttime/total)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.364","spread":"0.097"},{"groupId":"OG001","value":"0.961","spread":"0.099"},{"groupId":"OG002","value":"1.037","spread":"0.097"},{"groupId":"OG003","value":"1.217","spread":"0.097"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.051","spread":"0.125"},{"groupId":"OG001","value":"1.449","spread":"0.126"},{"groupId":"OG002","value":"1.471","spread":"0.125"},{"groupId":"OG003","value":"1.701","spread":"0.124"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.390","spread":"0.196"},{"groupId":"OG001","value":"2.399","spread":"0.198"},{"groupId":"OG002","value":"2.488","spread":"0.196"},{"groupId":"OG003","value":"2.917","spread":"0.195"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Rating (PGR) at 6 Weeks","description":"Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.1"},{"groupId":"OG001","value":"3.0","spread":"0.1"},{"groupId":"OG002","value":"3.1","spread":"0.1"},{"groupId":"OG003","value":"3.1","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Rating (PGR) at 12 Weeks","description":"Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.1"},{"groupId":"OG001","value":"3.0","spread":"0.1"},{"groupId":"OG002","value":"2.9","spread":"0.1"},{"groupId":"OG003","value":"3.0","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Rating (PGR) at 24 Weeks","description":"Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"0.1"},{"groupId":"OG001","value":"2.9","spread":"0.1"},{"groupId":"OG002","value":"2.9","spread":"0.1"},{"groupId":"OG003","value":"3.0","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Rating (PGR) at 48 Weeks","description":"Patient's Global Rating (PGR) was a patient assessment of their health (respiratory condition) at each visit (compared to the day before they started study drug) and ranged from 1 (very much better) to 7 (very much worse).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"0.1"},{"groupId":"OG001","value":"3.0","spread":"0.1"},{"groupId":"OG002","value":"2.9","spread":"0.1"},{"groupId":"OG003","value":"2.9","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Mahler Transitional Dyspnea Index Focal Score at 6 Weeks","description":"Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.995","spread":"0.248"},{"groupId":"OG001","value":"1.566","spread":"0.236"},{"groupId":"OG002","value":"1.660","spread":"0.240"},{"groupId":"OG003","value":"1.753","spread":"0.243"}]}]}]},{"type":"SECONDARY","title":"Mahler Transitional Dyspnea Index Focal Score at 12 Weeks","description":"Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.412","spread":"0.252"},{"groupId":"OG001","value":"1.792","spread":"0.239"},{"groupId":"OG002","value":"1.955","spread":"0.242"},{"groupId":"OG003","value":"1.805","spread":"0.245"}]}]}]},{"type":"SECONDARY","title":"Mahler Transitional Dyspnea Index Focal Score at 18 Weeks","description":"Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.665","spread":"0.254"},{"groupId":"OG001","value":"1.897","spread":"0.240"},{"groupId":"OG002","value":"2.099","spread":"0.244"},{"groupId":"OG003","value":"1.689","spread":"0.246"}]}]}]},{"type":"SECONDARY","title":"Mahler Transitional Dyspnea Index Focal Score at 32 Weeks","description":"Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.732","spread":"0.257"},{"groupId":"OG001","value":"1.898","spread":"0.241"},{"groupId":"OG002","value":"1.698","spread":"0.247"},{"groupId":"OG003","value":"1.966","spread":"0.249"}]}]}]},{"type":"SECONDARY","title":"Mahler Transitional Dyspnea Index Focal Score at 40 Weeks","description":"Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.952","spread":"0.259"},{"groupId":"OG001","value":"1.839","spread":"0.241"},{"groupId":"OG002","value":"1.887","spread":"0.249"},{"groupId":"OG003","value":"1.575","spread":"0.251"}]}]}]},{"type":"SECONDARY","title":"Mahler Transitional Dyspnea Index Focal Score at 48 Weeks","description":"Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.940","spread":"0.259"},{"groupId":"OG001","value":"2.035","spread":"0.242"},{"groupId":"OG002","value":"2.324","spread":"0.250"},{"groupId":"OG003","value":"2.047","spread":"0.251"}]}]}]},{"type":"SECONDARY","title":"Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"268","spread":null},{"groupId":"OG002","value":"136","spread":null},{"groupId":"OG003","value":"189","spread":null},{"groupId":"OG004","value":"134","spread":null},{"groupId":"OG005","value":"209","spread":null},{"groupId":"OG006","value":"223","spread":null},{"groupId":"OG007","value":"310","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Chronic Obstructive Pulmonary Disease (CPOD) Exacerbation Leading to Hospitalization","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"NA","spread":null},{"groupId":"OG005","value":"NA","spread":null},{"groupId":"OG006","value":"NA","spread":null},{"groupId":"OG007","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Moderate Chronic Obstructive Pulmonary Disease (CPOD) Exacerbation","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"296","spread":null},{"groupId":"OG002","value":"239","spread":null},{"groupId":"OG003","value":"244","spread":null},{"groupId":"OG004","value":"175","spread":null},{"groupId":"OG005","value":"302","spread":null},{"groupId":"OG006","value":"280","spread":null},{"groupId":"OG007","value":"270","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of COPD Exacerbations","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5684","spread":"0.0718"},{"groupId":"OG001","value":"0.7117","spread":"0.0793"},{"groupId":"OG002","value":"0.6946","spread":"0.0801"},{"groupId":"OG003","value":"0.5098","spread":"0.0649"}]}]}]},{"type":"SECONDARY","title":"Number of COPD Exacerbations Requiring Hospitalization","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0554","spread":"0.0249"},{"groupId":"OG001","value":"0.1043","spread":"0.0378"},{"groupId":"OG002","value":"0.1324","spread":"0.0493"},{"groupId":"OG003","value":"0.0570","spread":"0.0227"}]}]}]},{"type":"SECONDARY","title":"Number of Moderate Chronic Obstructive Pulmonary Disease (CPOD) Exacerbations","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4765","spread":"0.0645"},{"groupId":"OG001","value":"0.5537","spread":"0.0674"},{"groupId":"OG002","value":"0.5114","spread":"0.0654"},{"groupId":"OG003","value":"0.3721","spread":"0.0537"}]}]}]},{"type":"SECONDARY","title":"Absolute Plasma Concentrations","description":"Absolute plasma concentrations of Olodaterol. Values presented are across visits and summarised into geometric means.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"4.179","spread":"60.300"},{"groupId":"OG002","value":"7.246","spread":"72.242"}]}]}]},{"type":"SECONDARY","title":"Changes in Safety Parameters Related to Treatment","description":"Occurence of cardiac disorders and investigations related to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.4","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.4","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.4","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Mahler Transitional Dyspnea Index Focal Score at 24 Weeks for Combined Analysis","description":"This outcome measure describes the combined analysis of the trials NCT00793624 and NCT00796653. Mahler Transitional Dyspnea Index (TDI) focal score measures 3 components of dyspnea that evoke dyspnea in daily living: Functional Impairment, Magnitude of Task, and Magnitude of Effort. The TDI measures the change from the baseline assessment ranging from -9 (most deterioration) to +9 (most improvement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.471","spread":"0.155"},{"groupId":"OG001","value":"1.980","spread":"0.175"},{"groupId":"OG002","value":"1.996","spread":"0.170"},{"groupId":"OG003","value":"1.827","spread":"0.168"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":31,"n":225},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection","Cough","Dyspnoea"]}}}